Abstract
N-type Ca2+ channels can be inhibited by neurotransmitter-induced release of G protein βγ subunits. Two isoforms of Cav2.2 α1 subunits of N-type calcium channels from rat brain (Cav2.2a and Cav2.2b; initially termed rbB-I and rbB-II) have different functional properties. Unmodulated Cav2.2b channels are in an easily activated “willing” (W) state with fast activation kinetics and no prepulse facilitation. Activating G proteins shifts Cav2.2b channels to a difficult to activate “reluctant” (R) state with slow activation kinetics; they can be returned to the W state by strong depolarization resulting in prepulse facilitation. This contrasts with Cav2.2a channels, which are tonically in the R state and exhibit strong prepulse facilitation. Activating or inhibiting G proteins has no effect. Thus, the R state of Cav2.2a and its reversal by prepulse facilitation are intrinsic to the channel and independent of G protein modulation. Mutating G177 in segment IS3 of Cav2.2b to E as in Cav2.2a converts Cav2.2b tonically to the R state, insensitive to further G protein modulation. The converse substitution in Cav2.2a, E177G, converts it to the W state and restores G protein modulation. We propose that negatively charged E177 in IS3 interacts with a positive charge in the IS4 voltage sensor when the channel is closed and produces the R state of Cav2.2a by a voltage sensor-trapping mechanism. G protein βγ subunits may produce reluctant channels by a similar molecular mechanism.
Keywords: neuromodulation, G protein, voltage sensor, facilitation
Voltage-gated N-type Ca2+ currents play a central role in regulating the release of neurotransmitters (1–3), and N-type Ca2+ channels containing Cav2.2 α1 subunits (4–6) are highly concentrated in nerve terminals (7, 8). N-type channels are inhibited by activation of G protein-coupled receptors (9), which regulate neurotransmitter release by means of a negative feedback loop (10, 11). G protein inhibition is mediated by Gβγ subunits (12, 13), which bind to multiple target sites in the intracellular loop connecting domains I and II (LI-II) (14–17), the C terminus (18, 19), and the N terminus (20–23). Binding of G proteins is thought to cause a shift of gating mode from an easily activated “willing” (W) state to a “reluctant” (R) state (24). Strong depolarization shifts the channels back from the R state to the W state, producing prepulse facilitation (9, 25, 26).
Several different isoforms of Cav2.2 sharing >90% overall sequence identity have been cloned and functionally characterized (4, 5, 27–31). N-type Ca2+ channels cloned from rat brain have two isoforms, Cav2.2a and Cav2.2b originally designated rbB-I and rbB-II (4, 27, 29). In this study, we have examined the mechanism of G protein modulation and voltage-dependent facilitation of these two channel isoforms. Our results show that the Cav2.2a channel has intrinsic prepulse facilitation that is independent of G proteins, as if this channel is tonically in the R state, whereas the Cav2.2b channel shows G protein-dependent inhibition and prepulse facilitation consistent with the W state. This difference in channel gating and G protein modulation depends on a single amino acid difference in transmembrane segment IS3. The results lead to the conclusion that the reluctant state is intrinsic to the Cav2.2a channel in the absence of bound G protein. A voltage sensor-trapping mechanism, in which an S4 voltage sensor is stabilized in its inward, not-activated position, is proposed to account for the effect of this single amino acid difference and for modulation by Gβγ.
Experimental Procedures
Materials.
A recombinant cDNA encoding Cav2.2a from rat brain [originally called rbB-I (4)] was subcloned into pCDNA3 (Invitrogen). The cDNA encoding the Cav2.2b isoform was identical to rbB-II (29), except for insertion of A at position 415 in LI-II. It was subcloned into pMRC-CMV (Invitrogen). The β1b subunit was in the vector pMT2XS (27), α2δ in pZEM228 (32), and CD8 in EBO-pcD. Site-directed mutagenesis to construct Cav2.2a (E177G) was accomplished by replacing the BiswI–SrfI fragment of Cav2.2a with its corresponding fragment from Cav2.2b. Likewise, the Cav2.2b (G177E) mutation was generated by replacing the BiswI–SrfI fragment with its Cav2.2a counterpart.
Expression and Electrophysiology.
TsA-201 cells were maintained in DMEM/Ham's F-12 (1:1) supplemented with 10% FBS (Life Technologies, Rockville, MD) at 37°C under 10% CO2. Cells plated in 35-mm tissue culture dishes were grown to 60–80% confluence and transfected by the Ca2+ phosphate method with a total of 4 μg DNA including a 1:1 molar ratio of cDNAs encoding Ca2+ channel subunits and 0.3 μg of a CD8 expression plasmid for identification of transfected cells. The cells were subcultured at 24 h after the transfection. At least 48 h after transfection, positive transfected cells were visually identified by labeling with CD8-antibody-coated beads. Barium currents were recorded by the whole-cell patch clamp technique by using a List EPC-7 amplifier and filtered at 5 kHz with an eight-pole Bessel filter. Leak and capacitance currents were measured and subtracted by using the p/−4 method. The extracellular recording solution contained 120 mM Tris, 4 mM MgCl2, and 10 mM BaCl2 with pH adjusted to 7.3 by methanesulfonic acid. The internal pipette solution consisted of 120 mM aspartic acid, 5 mM CaCl2, 2 mM MgCl2, 10 mM Hepes, 10 mM EGTA, and 2 mM Mg-ATP with pH adjusted to 7.3 by CsOH. In some experiments, guanosine 5′-[γ-thio] triphosphate (GTPγS) was added to the internal solution at a concentration of 0.2 mM. Where indicated, guanosine 5′-O-(2-thiodi-phosphate) (GDPβS) was added to the internal solution to give a concentration of 2.0 mM. Somatostatin was dissolved in water to give a stock solution of 1 mM and added to the extracellular solution at a final concentration of 1 μM. N-Ethylmaleimide (NEM) were prepared in distilled water at 50 mM and added to the extracellular solution to give a final concentration of 50 μM. All agents were purchased from Sigma unless otherwise mentioned. All averaged values represent mean ± SEM.
Results
Kinetics and Voltage-Dependence of Activation of Different Cav2.2 Channels.
Ca2+ channels consisting of the Cav2.2a or Cav2.2b α1 subunits, α2δ subunits, and β1b subunits were expressed in the tsA-201 subclone of HEK293 cells as described in Experimental Procedures. These two Ca2+ channels have strikingly different functional properties (Fig. 1A). Ca2+ channels containing Cav2.2b exhibit fast activation (τact = 1.42 ± 0.08 ms, n = 4) and inactivation (τinact = 128 ± 10.8 ms, n = 4). In contrast, Cav2.2a activates and inactivates slowly (τact = 46.6 ± 5.3 ms, n = 6; τinact = 264 ± 28 ms, n = 6). In addition to this kinetic difference, the midpoint of the conductance–voltage curve of Cav2.2a is more positive (Va = 54.2 ± 2.2 mV, n = 16; Fig. 1B) and less steep in comparison to Cav2.2b (Va = 35.1 ± 5.4 mV, n = 18; Fig. 1B).
Effect of a Single Amino Acid Change in Transmembrane Segment IS3 on Activation of Cav2.2 Channels.
There are at least four sites of alternative amino acid residues in Cav2.2: (i) a glycine (G) to glutamate (E) substitution at position 177 in segment S3 in domain I; (ii) an E to G substitution at position 387 in LI-II; (iii) the absence of alanine (A) at position 415 in LI-II; and (iv) the absence of SFMG in the S3–S4 linker in domain III. Previous experiments have shown that the amino acid sequence differences in LI-II and in segment IIIS3–S4 have small, but significant, effects on Ca2+ currents (30, 31). However, these sequence differences are not responsible for the major change in the rate and voltage dependence of activation illustrated in Fig. 1 A and B. To examine the functional properties of Ca2+ channels differing only at position 177, we analyzed Cav2.2a(E177G) and Cav2.2b(G177E) by whole-cell voltage clamp. Cav2.2a(E177G) activated and inactivated rapidly like Cav2.2b (Fig. 1C; τact = 1.39 ± 0.11 ms, n = 4; τinact = 128.2 ± 25.8 ms, n = 4). The converse mutation, Cav2.2b(G177E), resulted in slow kinetics of activation, similar to Cav2.2a (Fig. 1C; τact = 40.8 ± 8.7 ms, n = 4; τinact = 243 ± 45, n = 4). In addition, the voltage dependence of activation of these two mutants also was altered as expected if this single amino acid change is responsible for the functional differences between Cav2.2a and Cav2.2b (Fig. 1D). For Cav2.2a(E177G), Va was 23.6 ± 3.9 mV (n = 6), similar to Cav2.2b. Conversely, for Cav2.2b(G177E), Va was 44.3 ± 2.8 mV (n = 9), more than 10 mV positive to wild-type Cav2.2b and similar to wild-type Cav2.2a. Thus, the amino acid residue at position 177 is responsible for nearly all of the difference in kinetics and voltage dependence of activation between Cav2.2a and Cav2.2b.
G Protein Activation and Prepulse Facilitation of Cav2.2 Channel Isoforms.
The slow activation kinetics and positive voltage dependence of activation of Cav2.2a resemble N-type Ca2+ channels following G protein modulation. To examine G protein modulation of these Ca2+ channels, we induced prepulse facilitation without and with GTPγS in the recording pipette to activate endogenous G proteins (see Inset to Fig. 2A). Facilitation during the prepulse was assessed by comparing the tail current following Test Pulse 2 to the tail current following Test Pulse 1. In the absence of G protein modulation, Cav2.2b channels activate rapidly at relatively negative membrane potentials (Fig. 2 A and B). A depolarizing prepulse has no effect on the rate or voltage dependence of activation (Fig. 2 A and B). Activation of G proteins with GTPγS slows activation of Cav2.2b and shifts its voltage dependence of activation to more positive membrane potentials (Fig. 2 C and D). Depolarizing prepulses cause an obvious facilitation (Fig. 2 C and D), resulting from voltage-dependent reversal of G protein inhibition.
In contrast to these results with Cav2.2b, Cav2.2a channels are slowly activated and have strong prepulse facilitation without G protein activation (Fig. 3 A and B). Activation of G proteins by GTPγS has no further effect on the kinetics or voltage dependence of activation or on prepulse facilitation (Fig. 3 C and D). These results indicate that the Cav2.2a channel has intrinsic facilitation, independent of G protein modulation.
To test whether the prepulse facilitation of Cav2.2a is truly independent of G protein action, we examined the effects of G protein inhibitors. Inhibition of G protein activity by including GDPβS (2 mM) in the pipette had no effect on prepulse facilitation of Cav2.2a (33). The sulfhydryl reagent NEM is a more potent inhibitor of G protein action (34). Addition of 50 μM NEM to the extracellular solution blocked somatostatin-induced facilitation of Cav2.2b in our transfected cells, confirming that it is an effective inhibitor of G protein modulation of these Ca2+ channels (data not shown). NEM also blocked facilitation of Cav2.2b channels, which is observed in a small percentage of cells in the absence of GTPγS stimulation (Fig. 4A). This indicates that the rare cells having measurable facilitation of Cav2.2b channels in the absence of GTPγS have constitutively active G proteins, which cause tonic inhibition of Ca2+ currents and allow prepulse facilitation (Fig. 4A). In most cells expressing Cav2.2b, no measurable facilitation is observed in the absence of GTPγS, and NEM has no effect on Ca2+ channel function (data not shown). In contrast to these results with Cav2.2b, NEM had no effect on facilitation of Ca2+ currents conducted by Cav2.2a (Fig. 4B). These results support the conclusion that facilitation of Cav2.2a is intrinsic to the Ca2+ channel and does not require G proteins. Evidently, the Ca2+ channel itself is capable of entering a slowly activated, reluctant state that is responsive to prepulse facilitation.
Effect of the Amino Acid at Position 177 on G Protein Modulation.
To determine whether the amino acid at position 177 affects G protein modulation, we performed prepulse facilitation experiments with Cav2.2a(E177G). These mutant channels have fast activation without a depolarizing prepulse, and it is not further accelerated after a depolarizing prepulse (Fig. 5A). Similarly, the voltage dependence of activation of Cav2.2a(E177G) is also unaffected by a depolarizing prepulse (Fig. 5B). In addition, this mutant channel is subject to G protein modulation, as determined by prepulse facilitation (Fig. 5 C and D). In the presence of GTPγS, facilitation is induced, and the voltage dependence of activation is shifted to more negative values by a depolarizing prepulse (Fig. 5D). On the other hand, Cav2.2b(G177E) has slow activation kinetics and strong prepulse facilitation in the absence of GTPγS, like Cav2.2a (Fig. 6 A and B). This mutant is insensitive to further G protein modulation (Fig. 6 C and D). These results support the conclusion that the amino acid residue at position 177 in transmembrane segment IS3 determines the rate and voltage dependence of activation and the response to G proteins of the Cav2.2 channels.
Discussion
Regulation of Cav2.2 Channel Gating Mode by G Proteins.
The mechanism of modulation of N-type Ca2+ channels by G protein-coupled receptors has been proposed to be a shift from a “willing” gating mode, in which Ca2+ channels activate rapidly upon depolarization, to a “reluctant” gating mode, in which activation is slow and requires a more positive depolarization (24). In the accompanying article (33), we show that an allosteric model based on this idea successfully accounts for regulation by Gβγ, prepulse facilitation, protein kinase C, and Cavβ subunits, which are proposed to alter the equilibrium constant for the transition between R and W states. Allosteric regulation of Ca2+ channel gating mode by these disparate agents implies that the R and W states are intrinsic to the Ca2+ channel α1 subunit, and the equilibrium constant for the transition between them is shifted by these different effectors. Consistent with that idea, we show in this report that Cav2.2 channels can be maintained in the R state in the absence of G protein activation by a single change in amino acid sequence in their α1 subunit.
Cav2.2a Channels Are in a Reluctant Gating Mode Without Bound Gβγ.
We have shown that Cav2.2 channels containing Cav2.2a and Cav2.2b α1 subunits have intrinsic functional properties resembling the reluctant and willing gating modes, respectively. Cav2.2b activated more rapidly and at much more negative membrane potentials than Cav2.2a. Activation of G proteins with GTPγS slowed activation of Cav2.2b and shifted the voltage dependence of activation to more positive membrane potentials, but had no effect on these properties of Cav2.2a. Thus, G protein modulation is occluded in Cav2.2a channels, as if they are in an R state under basal conditions. Prepulse-dependent facilitation is observed for Cav2.2a in the absence of GTPγS, consistent with these channels being in a reluctant gating mode without G protein activation. In contrast, Cav2.2b requires G protein activation and the resulting slowing of activation and positive shift of its voltage dependence for prepulse facilitation. The functional properties and prepulse facilitation of Cav2.2a are not affected by inhibition of endogenous G proteins with GDPβS or NEM. The results with NEM are especially persuasive because this reagent is a noncompetitive inhibitor of G protein signaling whose action is not opposed by GTP or effector binding (34). Altogether, these results indicate that the Cav2.2a isoform of Cav2.2 channels is constitutively in a reluctant gating mode without G protein binding and can be shifted to the willing gating mode by depolarizing prepulses.
The Amino Acid At Position 177 in IS3 Determines Gating Mode.
Although there are at least four sites of molecular differences between Cav2.2a and Cav2.2b, our results show that the differences in the kinetics and voltage dependence of activation and in the response to G proteins between these Ca2+ channels are determined primarily by the identity of the amino acid at position 177. When a glycine is present at this position, the channels are in a willing gating mode and are subject to G protein inhibition and subsequent prepulse facilitation. When a glutamate is present at this position, the channels are in a reluctant gating mode, strong prepulse facilitation is observed without G protein activation, and changes in the concentration of free Gβγ have little effect on channel function. Thus, the identity of this single amino residue determines the basal gating mode of Cav2.2 channels.
Although the gating and regulatory properties of Cav2.2a closely resemble those of reluctant Cav2.2b channels generated by activation of G proteins, detailed analysis revealed that activation is slower but is shifted less strongly toward positive potentials for Cav2.2a. Thus, the Cav2.2a channel in its basal state is not quantitatively identical to Cav2.2b after G protein regulation, even though it shares the main functional features of a reluctant gating mode. Similarly, the kinetics and voltage dependence of the willing gating mode of Cav2.2a(E177G) are not quantitatively identical to Cav2.2b. One of the other sites of known amino acid sequence difference among these isoforms (29, 31) may be responsible for these subtle differences in kinetics of gating.
There are at least two possible mechanisms for the tonically reluctant gating mode of Cav2.2a. Either this channel is tonically in an R state in the absence of G protein binding, or it has exceptionally high affinity for G proteins and can be modulated by the low level of Gβγ present in unstimulated cells. Our data favor the first conclusion because the G protein inhibitors GDPβS and NEM did not shift these channels to the W state. Evidently, the presence of a glutamate at position 177 in transmembrane segment IS3 is sufficient to shift Cav2.2 channels to a reluctant gating mode without binding of Gβγ subunits.
A Voltage Sensor-Trapping Mechanism for G Protein Modulation of Cav2.2 Channels.
Activation of voltage-gated sodium channels is initiated by the outward movement of positive gating charges in the S4 segments in each domain under the influence of the transmembrane electric field (35–39). Shift of N-type Ca2+ channels to the reluctant gating mode by G protein modulation slows the gating current caused by outward movement of the S4 voltage sensors preceding channel activation (40, 41), as if the outward movement of one or more S4 segments is slowed by Gβγ binding. Peptide neurotoxins alter sodium channel gating by binding to the S3–S4 loop at the extracellular end of the voltage-sensing S4 segments and altering their transmembrane movement by voltage-sensor trapping (42, 43). In the case of α-scorpion toxins, the S4 segment in domain IV of sodium channels is trapped in an inward position, but prolonged, strong depolarization causes dissociation of the bound toxin (44, 45), perhaps because of the voltage-driven outward movement of the IVS4 segment. Gβγ subunits may act in an analogous manner by binding to target sites on the intracellular surface of Cav2.2 channels and holding an S4 segment in its inward, not-activated position by protein–protein interactions. This molecular interaction would shift the equilibrium toward the R state by decreasing the equilibrium constant KWR in the allosteric model of Gβγ action described in the accompanying paper (33). Strong depolarization may push the S4 segment outward despite the bound G protein and thereby relieve G protein inhibition and favor channel activation.
The change of G177 to E in segment IS3 may also trap the S4 segment in an inward, not-activated position by electrostatic interactions. The positive charges in the S4 voltage sensors are thought to be stabilized in their membrane environment by ion pairing with negative charges in the S2 and S3 transmembrane segments (36). In support of this idea, a charge reversal mutation of E293 in S2 or D316 in S3 of Shaker potassium channels dramatically affects voltage-dependent gating (46–49). We propose that the negative charge at E177 forms a local electrostatic interaction with one of the positively charged residues of the IS4 segment. When this ion pair is formed, moving the IS4 segment outward would require more energy, and activation gating would be slowed and shifted to more positive potentials.
Although the Ca2+ channel has four voltage sensors, we find that a single mutation in transmembrane segment IS3 results in striking changes in kinetics and voltage dependence of activation. G177 speeds up activation of the channel, whereas E177 slows activation. These results indicate that the IS4 is the rate-limiting voltage sensor in the Cav2.2a channel. The IS3 segment is a primary determinant of the rate of activation of Cav1 channels (50), consistent with the hypothesis that the change of G177 to E in IS3 of Cav2.2 may act through interaction with IS4 gating charges to oppose channel activation.
The voltage sensor trapping mechanism of action of G proteins on Cav2.2 channels implies that bound G protein βγ subunits interact with the intracellular end of an S4 segment and hold it in an inward position. This interaction could be direct or mediated indirectly through one of the known G protein interaction sites on the Cav2.2 channel. The presence of G protein interaction sites (14–17), sites of protein kinase C modulation (17), and a site of Cavβ subunit binding (51) in LI-II points to the S4 segments in domains I and II as the most likely targets. Identification of a molecular interaction between G protein βγ subunits and the intracellular end of an S4 segment would provide direct biochemical evidence for the voltage sensor-trapping mechanism of G protein action proposed here on the basis of functional studies.
Acknowledgments
We thank Dr. Charles Chavkin and Dr. Kenneth Mackie for comments on a draft of the manuscript. This work was supported by Research Grant N522625 from the National Institutes of Health to W.A.C. and a postdoctoral fellowship from the Medical Research Council of Canada to H.Z.
Abbreviation
- W
willing
- R
reluctant
- GTPγS
guanosine 5′-[γ-thio] triphosphate
- GDPβS
guanosine 5′-O-(2-thiodi-phosphate)
- NEM
N-ethylmaleimide
References
- 1.Hirning L D, Fox A P, McCleskey E W, Olivera B M, Thayer S A, Miller R J, Tsien R W. Science. 1988;239:57–61. doi: 10.1126/science.2447647. [DOI] [PubMed] [Google Scholar]
- 2.Turner T J, Adams M E, Dunlap K. Proc Natl Acad Sci USA. 1993;90:9518–9522. doi: 10.1073/pnas.90.20.9518. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Dunlap K, Luebke J I, Turner T J. Trends Neurosci. 1995;18:89–98. [PubMed] [Google Scholar]
- 4.Dubel S J, Starr T V B, Hell J, Ahlijanian M K, Enyeart J J, Catterall W A, Snutch T P. Proc Natl Acad Sci USA. 1992;89:5058–5062. doi: 10.1073/pnas.89.11.5058. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Williams M E, Brust P F, Feldman D H, Patthi S, Simerson S, Maroufi A, McCue A F, Velicelebi G, Ellis S B, Harpold M M. Science. 1992;257:389–395. doi: 10.1126/science.1321501. [DOI] [PubMed] [Google Scholar]
- 6.Ertel E, Campbell K P, Harpold M M, Hofmann F, Mori Y, Perez-Reyes E, Schwartz A, Snutch T, Tanabe T, Birnbaumer L, et al. Neuron. 2000;25:533–535. doi: 10.1016/s0896-6273(00)81057-0. [DOI] [PubMed] [Google Scholar]
- 7.Westenbroek R E, Hell J W, Warner C, Dubel S J, Snutch T P, Catterall W A. Neuron. 1992;9:1099–1115. doi: 10.1016/0896-6273(92)90069-p. [DOI] [PubMed] [Google Scholar]
- 8.Westenbroek R E, Sakurai T, Elliott E M, Hell J W, Starr T V B, Snutch T P, Catterall W A. J Neurosci. 1995;15:6403–6418. doi: 10.1523/JNEUROSCI.15-10-06403.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Hille B. Trends Neurosci. 1994;17:531–536. doi: 10.1016/0166-2236(94)90157-0. [DOI] [PubMed] [Google Scholar]
- 10.Lipscombe D, Kongsamut S, Tsien R W. Nature (London) 1989;340:639–642. doi: 10.1038/340639a0. [DOI] [PubMed] [Google Scholar]
- 11.Brody D, Yue D. J Neurosci. 2000;20:889–898. doi: 10.1523/JNEUROSCI.20-03-00889.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Ikeda S R. Nature (London) 1996;380:255–258. doi: 10.1038/380255a0. [DOI] [PubMed] [Google Scholar]
- 13.Herlitze S, Garcia D E, Mackie K, Hille B, Scheuer T, Catterall W A. Nature (London) 1996;380:258–262. doi: 10.1038/380258a0. [DOI] [PubMed] [Google Scholar]
- 14.Herlitze S, Hockerman G H, Scheuer T, Catterall W A. Proc Natl Acad Sci USA. 1997;94:1512–1516. doi: 10.1073/pnas.94.4.1512. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.De Waard M, Liu H Y, Walker D, Scott V E S, Gurnett C A, Campbell K P. Nature (London) 1997;385:446–450. doi: 10.1038/385446a0. [DOI] [PubMed] [Google Scholar]
- 16.Page K M, Stephens G J, Berrow N S, Dolphin A C. J Neurosci. 1997;17:1330–1338. doi: 10.1523/JNEUROSCI.17-04-01330.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Zamponi G W, Bourinet E, Nelson D, Nargeot J, Snutch T P. Nature (London) 1997;385:442–446. doi: 10.1038/385442a0. [DOI] [PubMed] [Google Scholar]
- 18.Furukawa T, Nukada T, Mori Y, Wakamori M, Fujita Y, Ishida H, Fukuda K, Kato S, Yoshii M. J Biol Chem. 1998;273:17585–9498. doi: 10.1074/jbc.273.28.17585. [DOI] [PubMed] [Google Scholar]
- 19.Qin N, Platano D, Olcese R, Stefani E, Birnbaumer L. Proc Natl Acad Sci USA. 1997;94:8866–8871. doi: 10.1073/pnas.94.16.8866. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Page K M, Cantí C, Stephens G J, Berrow N S, Dolphin A C. J Neurosci. 1998;18:4815–4824. doi: 10.1523/JNEUROSCI.18-13-04815.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Canti C, Page K M, Stephens G J, Dolphin A C. J Neurosci. 1999;19:6855–6864. doi: 10.1523/JNEUROSCI.19-16-06855.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Simen A A, Miller R J. J Neurosci. 1998;18:3689–3698. doi: 10.1523/JNEUROSCI.18-10-03689.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Simen A A, Miller R J. Mol Pharmacol. 2000;57:1064–1074. [PubMed] [Google Scholar]
- 24.Bean B P. Nature (London) 1989;340:153–156. doi: 10.1038/340153a0. [DOI] [PubMed] [Google Scholar]
- 25.Marchetti C, Carbone E, Lux H D. Pflugers Arch. 1986;406:104–111. doi: 10.1007/BF00586670. [DOI] [PubMed] [Google Scholar]
- 26.Tsunoo A, Yoshii M, Narahashi T. Proc Natl Acad Sci USA. 1986;83:9832–9836. doi: 10.1073/pnas.83.24.9832. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Stea A, Dubel S J, Pragnell M, Leonard J P, Campbell K P, Snutch T P. Neuropharmacology. 1993;32:1103–1116. doi: 10.1016/0028-3908(93)90005-n. [DOI] [PubMed] [Google Scholar]
- 28.Coppola T, Waldmann R, Borsotto M, Heurteaux C, Romey G, Mattéi M-G, Lazdunski M. FEBS Lett. 1994;338:1–5. doi: 10.1016/0014-5793(94)80105-3. [DOI] [PubMed] [Google Scholar]
- 29.Stea A, Soong T W, Snutch T P. Neuron. 1995;15:929–940. doi: 10.1016/0896-6273(95)90183-3. [DOI] [PubMed] [Google Scholar]
- 30.Lin Z X, Haus S, Edgerton J, Lipscombe D. Neuron. 1997;18:153–166. doi: 10.1016/s0896-6273(01)80054-4. [DOI] [PubMed] [Google Scholar]
- 31.Lin Z, Lin Y, Schorge S, Pan J Q, Beierlein M, Lipscombe D. J Neurosci. 1999;19:5322–5331. doi: 10.1523/JNEUROSCI.19-13-05322.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Ellis S B, Williams M E, Ways N R, Brenner R, Sharp A H, Leung A T, Campbell K P, McKenna E, Koch W J, Hui A, et al. Science. 1988;241:1661–1664. doi: 10.1126/science.2458626. [DOI] [PubMed] [Google Scholar]
- 33.Herlitze S, Zhong H, Scheuer T, Catterall W A. Proc Natl Acad Sci USA. 2001;98:4699–4704. doi: 10.1073/pnas.051628998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Shapiro M S, Wollmuth L P, Hille B. J Neurosci. 1994;14:7109–7116. doi: 10.1523/JNEUROSCI.14-11-07109.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Guy H R, Seetharamulu P. Proc Natl Acad Sci USA. 1986;83:508–512. doi: 10.1073/pnas.83.2.508. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Catterall W A. Trends Neurosci. 1986;9:7–10. doi: 10.1016/0166-2236(93)90193-p. [DOI] [PubMed] [Google Scholar]
- 37.Stuhmer W, Conti F, Suzuki H, Wang X, Noda M, Yahadi N, Kubo H, Numa S. Nature (London) 1989;339:597–603. doi: 10.1038/339597a0. [DOI] [PubMed] [Google Scholar]
- 38.Yang N B, George A L, Jr, Horn R. Neuron. 1996;16:113–122. doi: 10.1016/s0896-6273(00)80028-8. [DOI] [PubMed] [Google Scholar]
- 39.Catterall W A. Neuron. 2000;26:13–25. doi: 10.1016/s0896-6273(00)81133-2. [DOI] [PubMed] [Google Scholar]
- 40.Patil P G, De. Leon M, Reed R R, Dubel S, Snutch T P, Yue D T. Biophys J. 1996;71:2509–2521. doi: 10.1016/S0006-3495(96)79444-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Jones L P, Patil P G, Snutch T P, Yue D T. J Physiol (London) 1997;498:601–610. doi: 10.1113/jphysiol.1997.sp021886. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Rogers J C, Qu Y, Tanada T N, Scheuer T, Catterall W A. J Biol Chem. 1996;271:15950–15962. doi: 10.1074/jbc.271.27.15950. [DOI] [PubMed] [Google Scholar]
- 43.Cestèle S, Qu Y, Rogers J C, Rochat H, Scheuer T, Catterall W A. Neuron. 1998;21:919–931. doi: 10.1016/s0896-6273(00)80606-6. [DOI] [PubMed] [Google Scholar]
- 44.Catterall W A. J Gen Physiol. 1979;74:375–391. doi: 10.1085/jgp.74.3.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Catterall W A. J Biol Chem. 1977;252:8660–8668. [PubMed] [Google Scholar]
- 46.Papazian D M, Shao X M, Seoh S-A, Mock A F, Huang Y, Wainstock D H. Neuron. 1995;14:1293–1301. doi: 10.1016/0896-6273(95)90276-7. [DOI] [PubMed] [Google Scholar]
- 47.Tiwari-Woodruff S K, Lin M A, Schulteis C T, Papazian D M. J Gen Physiol. 2000;115:123–138. doi: 10.1085/jgp.115.2.123. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Seoh S A, Sigg D, Papazian D M, Bezanilla F. Neuron. 1996;16:1159–1167. doi: 10.1016/s0896-6273(00)80142-7. [DOI] [PubMed] [Google Scholar]
- 49.Tiwari-Woodruff S K, Schulteis C T, Mock A F, Papazian D M. Biophys J. 1997;72:1489–1500. doi: 10.1016/S0006-3495(97)78797-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Nakai J, Adams B A, Imoto K, Beam K G. Proc Natl Acad Sci USA. 1994;91:1014–1018. doi: 10.1073/pnas.91.3.1014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Pragnell M, De Waard M, Mori Y, Tanabe T, Snutch T P, Campbell K P. Nature (London) 1994;368:67–70. doi: 10.1038/368067a0. [DOI] [PubMed] [Google Scholar]